National Expert Visits UC to Discuss Maternal-Fetal Surgery Debate
Larry Churchill, PhD, Ann Geddes Stahlman Chair of Medical Ethics at
Churchill will explore how religious convictions and optimistic expectations about maternal-fetal clinical trials can threaten the informed consent process and raise issues about recruitment and participation.
His talk will center on why parents agree to participate in a highly publicized and risky Vanderbilt clinical trial that uses innovative surgical techniques to treat fetuses with spina bifida lesions at 16 to 20 weeks gestation.
The surgery has recently drawn controversy and skepticism from the medical communityespecially neurosurgeonsand religious groups that question whether the benefits of the surgery outweigh the risks.
Religion is a powerful source of ethical norms that shapes interpretations and actions, says Churchill. Parents agreeing to participate in this highly controversial study displayed a lot of what I call common moral wisdomor reasoning through stories, parables, hunches or religious beliefs.
This, he says, raises questions about medical ethics and how physicians and clinical investigators should handle their patients religious views.
Churchill is widely published on the effects of medical ethics on human subjects, end of life decision making, social justice and
Churchill has a doctorate and a masters of divinity from
UCs Hutton Lectureship in Ethics, now in its third year, is an endowed lectureship named in honor of John Hutton, MD, former dean of the UC College of Medicine. Offered once a year, the lecture focuses on ethical topics facing todays health care system.
The lecture is free and open to the public, but reservations are encouraged. RSVP online at health.uc.edu/AlumniGiving/hutton.html or call (513) 558-0910.
Related Stories
Cancer Center plays key role in lab research, clinical trials for new pancreatic cancer drug
September 1, 2026
WLWT and WCPO highlighted the contributions of University of Cincinnati Cancer Center researchers that helped lead to the recent FDA approval of daraxonrasib, a new treatment for pancreatic cancer.
Cancer Center physician receives $150,000 New Investigator Research Grant to study treatment-resistant leukemia
September 1, 2026
The University of Cincinnati Cancer Center’s Sarah Skuli, MD, PhD, received a two‑year, $150,000 Leukemia Research Foundation New Investigator Grant to study TP53‑mutated leukemia, a treatment‑resistant subtype with very poor outcomes.
Heavy social media use linked to depression
August 31, 2026
U.S. News and World Report, Yahoo! News, MSN, USA Today and other national media highlight a new study by the University of Cincinnati and Northwestern University that found a correlation between heavy social media use and depression in adults.